These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 24793801)

  • 1. The role of the wearable cardioverter defibrillator in clinical practice.
    Chung MK
    Cardiol Clin; 2014 May; 32(2):253-70. PubMed ID: 24793801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator.
    Tanawuttiwat T; Garisto JD; Salow A; Glad JM; Szymkiewicz S; Saltzman HE; Kutalek SP; Carrillo RG
    Pacing Clin Electrophysiol; 2014 May; 37(5):562-8. PubMed ID: 24762055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?
    Barsheshet A; Vamvouris T; Goldenberg I
    Expert Rev Med Devices; 2016 Jul; 13(7):627-32. PubMed ID: 27333818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938
    [No Abstract]   [Full Text] [Related]  

  • 6. Fatal ventricular arrhythmias in myocarditis: A review of current indications for defibrillator devices.
    Imburgio S; Johal A; Akhlaq H; Klei L; Arcidiacono AM; Udongwo N; Mararenko A; Ajam F; Heaton J; Hansalia R; Zagha D
    J Cardiol; 2024 Sep; 84(3):151-154. PubMed ID: 38552838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction.
    Zaman S; Narayan A; Thiagalingam A; Sivagangabalan G; Thomas S; Ross DL; Kovoor P
    Circulation; 2014 Feb; 129(8):848-54. PubMed ID: 24381209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
    Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O
    J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wearable cardioverter-defibrillators: A review of evidence and indications.
    Cheung CC; Olgin JE; Lee BK
    Trends Cardiovasc Med; 2021 Apr; 31(3):196-201. PubMed ID: 32205034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Wearable Cardioverter-Defibrillator (WCD)].
    Helms TM; Müller A; Schwab JO; Bänsch D; Karle C; Klingenheben T; Zugck C; Perings C
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):129-33. PubMed ID: 25939989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD).
    Klein HU; Meltendorf U; Reek S; Smid J; Kuss S; Cygankiewicz I; Jons C; Szymkiewicz S; Buhtz F; Wollbrueck A; Zareba W; Moss AJ
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):353-67. PubMed ID: 19889186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The wearable cardioverter-defibrillator vest: Indications and ongoing questions.
    Sandhu U; Rajyaguru C; Cheung CC; Morin DP; Lee BK
    Prog Cardiovasc Dis; 2019; 62(3):256-264. PubMed ID: 31077726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The wearable cardioverter-defibrillator: current technology and evolving indications.
    Reek S; Burri H; Roberts PR; Perings C; Epstein AE; Klein HU; ; Lip G; Gorenek B; Sticherling C; Fauchier L; Goette A; Jung W; Vos MA; Brignole M; Elsner C; Dan GA; Marin F; Boriani G; Lane D; Blomström-Lundqvist C; Savelieva I
    Europace; 2017 Mar; 19(3):335-345. PubMed ID: 27702851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis.
    Piccini JP; Al-Khatib SM; Myers ER; Anstrom KJ; Buxton AE; Peterson ED; Sanders GD
    J Cardiovasc Electrophysiol; 2010 Jul; 21(7):791-8. PubMed ID: 20132397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Wearable Cardioverter Defibrillator as a Bridge to Implantable Cardioverter Defibrillator.
    Weinstock J
    Card Electrophysiol Clin; 2018 Mar; 10(1):11-16. PubMed ID: 29428131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.